Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 7/20 | 0.45 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25585039 | 0.85 | GRM5 (0.38) | CYP19A1CYP11B1CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL25587241 | 0.80 | GRM5 (0.45) | CYP19A1CYP11B1CYP11B2CYP3A4GRM4 | |
| SCHEMBL25587254 | 0.79 | CYP11B1 (0.47) | CYP19A1CYP11B1CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL25584836 | 0.79 | RIPK1 (0.47) | CYP19A1CYP11B1CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL30387134 | 0.79 | RIPK1 (0.47) | CYP19A1CYP11B1CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL23081632 | 0.77 | CYP11B1 (0.51) | CYP19A1CYP11B1CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL21859175 | 0.75 | NPC1 (0.46) | CYP11B1CYP11B2CYP3A4CYP1A2GRM4 | |
| SCHEMBL25587249 | 0.75 | BACE1 (0.42) | — | |
| SCHEMBL30832140 | 0.74 | SLC6A4 (0.40) | — | |
| SCHEMBL25556119 | 0.73 | CYP11B1 (0.46) | CYP19A1CYP11B1CYP11B2CYP3A4CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | CYP19A1 3084/4885CYP11B1 2676/4885CYP11B2 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.